The outcome of hematopoietic stem cell transplantation (HSCT) in patients with severe aplastic anemia (SAA) has improved considerably over the last few decades, 1 but graft rejection rates at 10-15%, acute GvHD grade II-IV rates at 11-26% and, particularly, chronic GvHD rates at 30% remain important challenges. 2, 3 Optimal transplantation strategies for patients undergoing HSCT from an HLA-matched sibling donor (MSD) are considered to be conditioning with cyclophosphamide (CY) and ATG, cyclosporin-A (CsA) and short-term methotrexate as GvHD prophylaxis and bone marrow (BM), as a stem cell source given lower GvHD risks. 4 However, the advantage of BM over PBSC may be less evident when modulated in vitro T-cell depletion is used. Here we report a series of 12 patients transplanted for SAA at the Bone Marrow Transplant Unit of the Geneva University Hospital with T-cell depleted PBSC followed by a T-cell add-back the next day. We report the incidence of post-transplant infections and an analysis of the hematopoietic chimerism associated with a low incidence of both acute and chronic GvHD, sustained engraftment and excellent long-term survival.
We retrospectively evaluated 12 consecutive patients with acquired SAA receiving first transplants from an MSD or HLA-matched unrelated donors after a conditioning regimen consisting of CY and ATG with partially T-cell-depleted PBSC from 1997 to 2015. All patients provided written informed consent. The stem cell source was G-CSF-mobilized peripheral blood of which a part was T-cell depleted with 20 mg of alemtuzumab (CAMPATH-1H (Genzyme Corporation, Cambridge, MA, USA)) in vitro for infusion at day 0, whereas the rest, containing 100 × 10 6 CD3+ cells/kg, was given as a T-cell add-back at day 1.
5
GvHD prophylaxis consisted of CsA, titrated to trough levels between 150 and 200 μg/L and continued for at least 12 months post HSCT in combination with a short course of methotrexate.
Patients and transplantation-related parameters, as well as hematological recovery data are presented in Table 1 . With a median follow-up of 91 months (range 4-131), all patients engrafted and are alive in sustained CR. No acute GvHD was observed, whereas moderate chronic GvHD occurred only in 1 patient.
Low hematopoietic stem cell doses are associated with an increased risk of graft failure. 6 Moreover, in order to ensure engraftment, 'the more the better' seems to be the rule. BM is strongly recommended as the stem cell source for all SAA patients in spite of the fact that it does not always contain an adequate cell dose. On the other hand, PBSC grafts contain considerably more cells, but their use is associated with an increased risk of GvHD and a higher mortality rate. 7, 8 Indeed, according to the European Society for Blood and Marrow Transplantation (EBMT) analysis of the outcome of 1448 SAA patients transplanted between 2005 and 2009, the use of PBSC as stem cell source is the strongest negative predictor of survival. 3 Our partially T-cell-depleted PBSC grafts that contain a median CD34+ cell dose of 9.7 × 10 6 /kg and not enough T cells to cause severe GvHD may be an efficient approach. Obviously, we do not pretend that the outcome of our small series calls into question the recommendation for BM donation, but we do think that our method may be considered in cases where transplanting with PBSC is the only available option. The favorable impact of in vivo T-depletion by alemtuzumabcontaining regimens in SAA transplants on the incidence and severity of GvHD has been noticed previously. [9] [10] [11] However, the increased risk of infections, particularly viral, associated with the use of alemtuzumab is of concern.
11 In our study, we assessed CD4+ T-cell counts and serum concentration of Igs, as well as the incidence and the severity of infections at different time points after transplantation. All patients displayed 4200 CD4+T cells/μL at 1 year after transplantation, but only 2 patients achieved normal values (4600 CD4+T cells/μL) during the first 5 years. The median serum IgG concentration was 5.8 g/L at 6 months and normalized (47 g/L) by 1 year. We observed eight severe bacterial and two possible invasive fungal infections during the pre-engraftment period, but only one severe infection -a successfully resolved respiratory syncytial virus bronchitisthereafter. Over time, CMV reactivation occurred in 6/10 patients at risk, but none developed CMV disease after pre-emptive treatment. Thus, we believe that in vitro T-cell depletion with add-back of a fixed T-cell dose results in a rapid, albeit incomplete immune reconstitution and a rather low risk of infections. A beneficial role of stable mixed chimerism (SMC) has been suggested in patients transplanted for nonmalignant diseases 12 or specifically for SAA 9, 13, 14 who developed significantly less acute and chronic GvHD. Indeed, SMC seems to be a more than acceptable outcome in the patients transplanted for SAA and its long-term persistence after immunosuppression withdrawal supports the hypothesis that a state of tolerance is achieved. In our study, we performed chimerism analysis of peripheral blood samples on day +30, +60, +90, +180, +360 and yearly thereafter on granulocytes and mononuclear cells (MNC) obtained by Ficoll density gradient centrifugation, with STRs polymorphisms of informative loci methods. 15 Chimerism analysis was performed separately on MNC and granulocytes in 11 patients and on unfractionated blood in 1. Full donor chimerism (FDC) was defined as the absence of cells of patient origin (detection threshold 1-3%), whereas mixed chimerism (MC) as the presence of both patient and donor cells. MC occurring during the first 6 months only was referred to as transient mixed chimerism (TMC), MC with o30% cells of patient origin as stable MC (SMC) and MC with 430% of recipient origin cells in two consecutive assessments over an at least 3-month analysis period as high MC. MNC were of mixed origin in 9/11 patients with sublineage chimerism data ( Figure 1a) . Two patients presented high MC from 6 and 3 months post HSCT, decreased to SMC levels by 1 and 6 years, respectively (Figure 1a ). Granulocytes were FDC during the entire period post HSCT in 6/11 patients, whereas the other 5 patients presented SMC with a constantly low proportion of cells of patient origin (Figure 1b) . The patient tested on whole blood exhibited SMC for the entire period after HSCT (not shown). No patient presented TMC. Hence we observed a high proportion of SMC that is more perceptible in MNC than in granulocytes. However, given that the near absence of recipient myelopoiesis in patients transplanted for SAA makes FDC in granulocytes of no importance, we believe that assessing chimerism status in MNC is more relevant. In our series, 10/12 patients finally developed SMC, which represents one of the higher SMC rates reported. As the conditioning regimen and the GvHD prophylaxis used do not differ from published series, this result is probably due to our partial T-cell-depletion method.
Our study presents several limitations; its retrospective nature and relatively long span, as well as its small sample size. Moreover, chimerism data are based on MNC and not on T-cell assessment. In spite of these drawbacks, we believe that our observation, showing that the use of partially T-cell-depleted PBSC grafts in SAA patients provides high stem cell doses with sufficient donor lymphocytes for durable engraftment and low rate of opportunistic infections, minimizes the inherent increased GvHD risk in PBSC and may promote the establishment of long-term SMC, deserves further investigative attention. 
